Composition for treating, preventing or relieving macular degeneration, containing vaccinium uliginosum extract or vaccinium uliginosum fractions as active ingredient

A technology of bilberry, macular degeneration, applied in the field of compositions for treating, preventing or improving macular degeneration

Active Publication Date: 2014-09-03
丁秀荣
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] Zeaxanthin and anthocyanins, which act as macular pigments such as lutein, are abundant in berries and have been reported to exhibit anti-AMD effects, but have not yet been approved by the FDA
Also, only a few studies have been done on the effect of this pigment on macular degeneration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating, preventing or relieving macular degeneration, containing vaccinium uliginosum extract or vaccinium uliginosum fractions as active ingredient
  • Composition for treating, preventing or relieving macular degeneration, containing vaccinium uliginosum extract or vaccinium uliginosum fractions as active ingredient
  • Composition for treating, preventing or relieving macular degeneration, containing vaccinium uliginosum extract or vaccinium uliginosum fractions as active ingredient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1: Preparation of Bilberry Extract

[0046] Fruits of well-shaped lingonberries are selected and washed. 2,000 mL of water was added to 100 g of fruit, followed by two rounds of hot water extraction at 90° C. for 16 hours to obtain 10% bilberry extract. This bilberry extract was freeze-dried, processed into a powder and stored at -40°C until used to prepare the bilberry fraction or for the experiments below.

Embodiment 2

[0047] Example 2: Preparation of lingonberry fractions

[0048] The powdered Vaccinium extract prepared in Example 1 was dissolved in distilled water. Separately, two C18Sep-Pak cartridges were interconnected and preconditioned with 10 mL of ethyl acetate and anhydrous methanol, then 0.01N aqueous HCl was passed through the cartridges.

[0049] Load the extract solution into the cartridge, and then use 6 mL of 0.01N HCl aqueous solution to elute carbohydrates, acids, and other water-soluble compounds. The eluate was collected as a carbohydrate / acid fraction, which was used as a comparison in subsequent experiments.

[0050] Then, the attached C18Sep-Pak cartridge was purged with nitrogen for 10 min to dry the above cartridge. Then, 20 mL of ethyl acetate was passed through the dry cartridge to elute the phenolic compound and collect the polyphenyl fraction in a test tube.

[0051] Then, anthocyanins were eluted with 10 mL of anhydrous methanol containing 0.1% HCl to obtain ...

Embodiment 3

[0054] Example 3: Cell Culture

[0055] Human adult ARPE cells (ARPE-19; number CRL-2302) used in the experiments and analyzes of the present invention were obtained from Vision Science Institute, Catholic University of Korea, School of Medicine. at 37°C and 5% CO 2 ARPE cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U / ml penicillin and 100 mg / ml streptomycin in an atmospheric incubator. cells in 5 x 10 4 Cells / well were seeded in 6-well plates. Example 4: A2E Synthesis

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a composition for treating, preventing or alleviating macular degeneration, the composition comprising bilberry extract or part of bilberry as an active ingredient. The active ingredients of the present invention, lingonberry extract and bilberry part, inhibit the accumulation of A2E in retinal pigment epithelial cells and inhibit the oxidation of A2E to effectively protect the retinal pigment epithelial cells, thereby preventing the cause of macular degeneration. Therefore, the composition of the present invention can be developed into various products, such as medicines, dietary supplements, etc., for excellent treatment or alleviation of macular degeneration.

Description

technical field [0001] The present invention relates to a composition for treating, preventing or improving macular degeneration, the composition comprising Vaccinium uliginosum extract or a fraction thereof as an active ingredient. Background technique [0002] The macula or macula lutea is the nerve tissue located near the center of the retina of the human eye and is primarily responsible for the eye's vision as it is the center of the visual field and is where most of the visual cells are concentrated and where images are located. Macular degeneration, caused by various factors, is a medical condition that causes visual impairment. Macular degeneration is one of three leading causes of irreversible blindness, the others being glaucoma and diabetic retinopathy. [0003] Macular degeneration resulting from damage to the center of the retina manifests itself in the form of various signs or symptoms (including central vision blurring, central scotoma, visual distortions in t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/45A61P27/02A61P43/00
CPCA61K36/45A61P27/02A61P43/00
Inventor 丁世荣
Owner 丁秀荣
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap